# Vertex Pharmaceuticals (Europe) (Vertex Pharmaceuticals (Europe) Limited) Private limited company registered in London, classed under “Other research and experimental development on natural sciences and engineering”. - Company number: 02907620 - Status: Active - Type: Private limited company - Incorporated: 11 March 1994 - Registered office: 2 Kingdom Street, London, W2 6BD - Location: London - Activity: Other research and experimental development on natural sciences and engineering ## Latest filed profit No profit figure in its latest filed accounts. Turnover, net assets, cash, staff, earlier years, ratios and owners are on the page for subscribers. ## Questions people ask ### What does Vertex Pharmaceuticals (Europe) do? Private limited company registered in London, classed under “Other research and experimental development on natural sciences and engineering”. ### How much turnover does Vertex Pharmaceuticals (Europe) make? Answered on the page for FirmFacts Pro subscribers: https://firmfacts.co/company/vertex-pharmaceuticals-europe-02907620 ### Is Vertex Pharmaceuticals (Europe) profitable? Vertex Pharmaceuticals (Europe)'s profit isn't public: small companies may file without a profit and loss account. ### Who runs and owns Vertex Pharmaceuticals (Europe)? Its directors are Jason Mark Brooks, Simon Kempin Lem, Prasanna Eknath Thombre, Omar Narayan White. Its owners are shown to subscribers. ### Where is Vertex Pharmaceuticals (Europe) based? Its registered office is 2 Kingdom Street, London, W2 6BD, in London. ### When was Vertex Pharmaceuticals (Europe) founded? Vertex Pharmaceuticals (Europe) Limited was incorporated on 11 March 1994. ### Is Vertex Pharmaceuticals (Europe) still trading? The register lists Vertex Pharmaceuticals (Europe) Limited as active. ## Timeline Recent filings and changes at Companies House. - 2026-09-14: Full accounts made up to 31 December 2025 - 2026-09-02: Termination of appointment of Jonathan Richard Oppenheim as a director on 27 August 2026 - 2025-08-19: Appointment of Jason Mark Brooks as a director on 8 August 2025 - 2025-08-15: Appointment of Omar Narayan White as a director on 8 August 2025 - 2025-08-15: Appointment of Prasanna Eknath Thombre as a director on 8 August 2025 - 2025-07-11: Full accounts made up to 31 December 2024 - 2025-07-07: Termination of appointment of Ashley Alexander Grist as a director on 1 July 2025 - 2025-03-25: Director's details changed for Simon Kempin Lem on 1 September 2024 - 2025-02-19: Notification of Vertex Pharmaceuticals Uk Holdings Limited as a person with significant control on 31 December 2024 - 2025-02-19: Cessation of Vertex Pharmaceuticals Incorporated as a person with significant control on 31 December 2024 - 2024-08-29: Full accounts made up to 31 December 2023 - 2024-05-31: Termination of appointment of Mitre Secretaries Limited as a secretary on 31 May 2024 - 2023-10-30: Full accounts made up to 31 December 2022 - 2022-09-28: Full accounts made up to 31 December 2021 - 2022-02-08: Appointment of Mr Jonathan Richard Oppenheim as a director on 8 February 2022 - 2021-12-06: Termination of appointment of Klas Alexander Holmlund as a director on 3 December 2021 - 2021-09-30: Full accounts made up to 31 December 2020 - 2020-06-11: Full accounts made up to 31 December 2019 - 2020-05-12: Resolutions - 2020-05-06: Statement of capital following an allotment of shares on 24 April 2020 · GBP 129,000 (and 3 more like it since 26 February 2015) - 2019-09-23: Full accounts made up to 31 December 2018 - 2019-04-26: Appointment of Mr Ashley Alexander Grist as a director on 19 April 2019 - 2019-04-26: Appointment of Mr Klas Alexander Holmlund as a director on 19 April 2019 - 2019-04-26: Termination of appointment of Ian Frederick Smith as a director on 23 January 2019 - 2019-04-26: Termination of appointment of Michele Bellandi as a director on 19 April 2019 --- Source: Companies House filings (Open Government Licence v3.0). Figures are as filed; nothing is estimated. Page: https://firmfacts.co/company/vertex-pharmaceuticals-europe-02907620